Biased Ligands. Better Drugs.

At Trevena, our mission is to deliver innovative medicines to patients and healthcare providers confronting serious medical conditions.

Oliceridine (TRV130), our lead product candidate with FDA Breakthrough Therapy Designation, is a next generation IV analgesic being studied for management of moderate-to-severe acute pain.

We are dedicated to discovering and developing therapies intended to provide valuable improvements to patient care.

Our pipeline includes several additional product candidates we have identified as potential best- or first-in-class therapies for a variety of critical unmet medical needs. These are all new molecules discovered by Trevena scientists using our proprietary ABLE™ platform.

Copyright © Trevena, Inc.